Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · IEX Real-Time Price · USD
5.72
-0.11 (-1.89%)
Jul 22, 2024, 10:33 AM EDT - Market open
Pasithea Therapeutics Employees
Pasithea Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 7 or -46.67% compared to the previous year.
Employees
8
Change (1Y)
-7
Growth (1Y)
-46.67%
Revenue / Employee
n/a
Profits / Employee
-$2,035,602
Market Cap
5.97M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | -7 | -46.67% |
Dec 31, 2022 | 15 | 10 | 200.00% |
Dec 31, 2021 | 5 | 2 | 66.67% |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
CareMax | 1,450 |
Telesis Bio | 147 |
ReShape Lifesciences | 29 |
Hepion Pharmaceuticals | 22 |
Soligenix | 15 |
Xenetic Biosciences | 4 |
GT Biopharma | 2 |
KTTA News
- 7 weeks ago - Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 - GlobeNewsWire
- 7 months ago - Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position - GlobeNewsWire
- 7 months ago - Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - GlobeNewsWire
- 7 months ago - Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 - GlobeNewsWire
- 7 months ago - Pasithea Therapeutics Announces Results from 2023 Annual Meeting - GlobeNewsWire